• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.

作者信息

Falconi Giulia, Fabiani Emiliano, Piciocchi Alfonso, Criscuolo Marianna, Fianchi Luana, Lindfors Rossi Elisa L, Finelli Carlo, Cerqui Elisa, Ottone Tiziana, Molteni Alfredo, Parma Matteo, Santarone Stella, Candoni Anna, Sica Simona, Leone Giuseppe, Lo-Coco Francesco, Voso Maria Teresa

机构信息

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, Italy.

Fondazione GIMEMA, Roma, Italy.

出版信息

Leukemia. 2019 Mar;33(3):785-790. doi: 10.1038/s41375-018-0284-9. Epub 2018 Oct 5.

DOI:10.1038/s41375-018-0284-9
PMID:30291338
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6462855/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43a9/6462855/8d6e997dc6e2/41375_2018_284_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43a9/6462855/8d6e997dc6e2/41375_2018_284_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43a9/6462855/8d6e997dc6e2/41375_2018_284_Fig1_HTML.jpg

相似文献

1
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.体细胞突变作为高危骨髓增生异常综合征接受阿扎胞苷和异基因干细胞移植后预后的标志物
Leukemia. 2019 Mar;33(3):785-790. doi: 10.1038/s41375-018-0284-9. Epub 2018 Oct 5.
2
Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.急性髓系白血病或骨髓增生异常综合征移植后复发患者接受阿扎胞苷治疗期间系列骨髓样本的突变分析。
Haematologica. 2017 Jun;102(6):e216-e218. doi: 10.3324/haematol.2016.162909. Epub 2017 Feb 16.
3
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome.涉及晚期巨核细胞生成的转录因子作为骨髓增生异常综合征患者接受阿扎胞苷和异基因干细胞移植后结局的标志物。
Leuk Res. 2019 Sep;84:106191. doi: 10.1016/j.leukres.2019.106191. Epub 2019 Jul 19.
4
Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.接受阿扎胞苷作为异基因干细胞移植桥梁治疗失败后进行挽救性诱导化疗的患者。
Br J Haematol. 2014 Jul;166(2):303-6. doi: 10.1111/bjh.12844. Epub 2014 Mar 21.
5
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?对于高危骨髓增生异常综合征患者，是否应在移植前进行减瘤治疗？
J Clin Oncol. 2013 Jul 20;31(21):2761-2. doi: 10.1200/JCO.2012.48.0525. Epub 2013 Jun 17.
6
Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome.高危骨髓增生异常综合征的移植前5-氮杂胞苷治疗
Biol Blood Marrow Transplant. 2014 Jun;20(6):776-80. doi: 10.1016/j.bbmt.2014.02.008. Epub 2014 Feb 15.
7
Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes.在驶入针对骨髓增生异常综合征患者的干细胞移植这片波涛汹涌的海域之前调整索具。
Biol Blood Marrow Transplant. 2012 Aug;18(8):1145-7. doi: 10.1016/j.bbmt.2012.05.004. Epub 2012 May 15.
8
Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center.
Bone Marrow Transplant. 2010 Aug;45(8):1375-6. doi: 10.1038/bmt.2009.355. Epub 2009 Dec 21.
9
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.阿扎胞苷对急性髓系白血病异基因干细胞移植后复发患者的临床活性。
Haematologica. 2016 Jul;101(7):879-83. doi: 10.3324/haematol.2015.140996. Epub 2016 Apr 14.
10
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.异基因造血干细胞移植前应用阿扎胞苷治疗骨髓增生异常综合征：法国骨髓移植和细胞治疗学会与法语区骨髓增生异常综合征协作组研究
J Clin Oncol. 2012 Dec 20;30(36):4533-40. doi: 10.1200/JCO.2012.44.3499. Epub 2012 Oct 29.

引用本文的文献

1
TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.TP53 突变的骨髓增生异常综合征和急性髓系白血病。
Mediterr J Hematol Infect Dis. 2023 Jul 1;15(1):e2023038. doi: 10.4084/MJHID.2023.038. eCollection 2023.
2
The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine.地西他滨治疗老年急性髓系白血病患者时，变异负担降低对预后的影响。
Korean J Intern Med. 2023 Jul;38(4):534-545. doi: 10.3904/kjim.2022.396. Epub 2023 Jun 9.
3
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.
迈向骨髓增生异常综合征中可测量残留疾病的概念化。
Blood Adv. 2023 Aug 22;7(16):4381-4394. doi: 10.1182/bloodadvances.2023010098.
4
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.聚乙二醇化阿扎胞苷克隆大小可预测骨髓增生异常综合征和相关髓系肿瘤患者的长期预后。
Blood Adv. 2023 Jul 25;7(14):3624-3636. doi: 10.1182/bloodadvances.2022009564.
5
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.我如何管理不符合移植条件的骨髓增生异常肿瘤患者。
Clin Hematol Int. 2023 Mar;5(1):8-20. doi: 10.1007/s44228-022-00024-4. Epub 2022 Dec 27.
6
Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.异质性遗传和非遗传机制导致了对阿扎胞苷单一疗法的反应和耐药性。
EJHaem. 2022 Jul 8;3(3):794-803. doi: 10.1002/jha2.527. eCollection 2022 Aug.
7
The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19.维奈克拉/阿扎胞苷联合疗法针对急性髓系白血病中的疾病克隆，对一名新冠肺炎患者有效且安全。
Mediterr J Hematol Infect Dis. 2022 May 1;14(1):e2022041. doi: 10.4084/MJHID.2022.041. eCollection 2022.
8
Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy.去甲基化治疗后癌基因的去甲基化和上调。
N Engl J Med. 2022 May 26;386(21):1998-2010. doi: 10.1056/NEJMoa2119771.
9
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.骨髓增生异常/骨髓增殖性肿瘤的基因组景观可预测低甲基化剂治疗的反应。
Leuk Lymphoma. 2022 Aug;63(8):1942-1948. doi: 10.1080/10428194.2022.2057488. Epub 2022 Apr 4.
10
R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.R882突变在骨髓增生异常综合征中赋予独特的临床病理特征，包括急性髓系白血病转化的高风险。
Front Oncol. 2022 Feb 28;12:849376. doi: 10.3389/fonc.2022.849376. eCollection 2022.